{"id":"dolutegravir-placebo-twice-daily","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4303416","moleculeType":"Small molecule","molecularWeight":"419.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dolutegravir (the active comparator) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing viral DNA from integrating into the host genome. The placebo arm in this Phase 3 trial allows researchers to measure the true clinical benefit of dolutegravir treatment versus no active intervention.","oneSentence":"This is a placebo control arm in a clinical trial; it contains no active drug and serves as a comparator to assess the efficacy of dolutegravir.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:55.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (Phase 3 trial comparator arm)"}]},"trialDetails":[{"nctId":"NCT01231516","phase":"PHASE3","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-26","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":724},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT01568892","phase":"PHASE3","title":"Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-04-18","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01498861","phase":"PHASE1","title":"Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-12","conditions":"Infection, Human Immunodeficiency Virus","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GSK1349572 Placebo"],"phase":"phase_3","status":"active","brandName":"Dolutegravir placebo twice daily","genericName":"Dolutegravir placebo twice daily","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm in a clinical trial; it contains no active drug and serves as a comparator to assess the efficacy of dolutegravir. Used for HIV-1 infection (Phase 3 trial comparator arm).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}